Bari

• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• A trial to learn how well balcinrenone in combination with dapagliflozin works and how safe it is compared to dapagliflozin alone in adults … Ended
  2023-509709-63-00 4 2024-07-30 Chronic Kidney Disease and Albuminuria
• An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal … Ended
  2023-507350-33-00 5 2024-06-25 Thyroid eye disease
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended
  2023-507217-10-00 5 2024-04-12 Thyroid eye disease
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to … Ended
  2023-504564-42-00 4 2024-04-08 Moderate to Severe Rheumatoid Arthritis
• A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to te … Ended
  2022-502467-38-00 4 2024-02-22 Non-small cell lung cancer (NSCLC)
• A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibul … Ended
  2023-505487-11-00 5 2023-12-21 Actinic Keratosis on the Face or Scalp
• A study to test whether BI 765845 helps people who have had a heart attack Ended
  2022-502788-39-00 4 2023-11-27 acute myocardial infarction
• A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended
  2022-502227-22-00 4 2023-10-25 Autoimmune disease
• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 5 2023-09-13 Macular edema secondary to retinal vein occlusion
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV … Ended
  2022-502620-49-00 2 2023-08-01 Resected Melanoma Stage III or Stage IV
• ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney … Ended
  2022-501802-36-00 5 2023-06-16 Prevention of cardiac surgery associated acute kidney injury
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended
  2024-513269-37-00 6 2023-03-14 Migraine attacks with or without aura
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan … Ended
  2024-513270-21-00 6 2023-03-14 migraine headaches with or without aura
• A study to evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of treatment in children and adolescents with ASD Ended
  2024-512202-25-00 4 2023-02-27 Irritability associated with autistic disorder in children and adolesc
• A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended
  2022-500350-42-01 10 2022-11-07 Prevention of RSV
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache

Showing 313–336 of 368 trials